| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.98.20.2141 |
| P698 | PubMed publication ID | 9815868 |
| P2093 | author name string | Just H | |
| Hasenfuss G | |||
| Pieske B | |||
| Castell M | |||
| Kretschmann B | |||
| Maier LS | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2141-2147 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium | |
| P478 | volume | 98 |
| Q36013080 | A review of levosimendan in the treatment of heart failure |
| Q42997884 | Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis. |
| Q36632217 | Acute heart failure: inotropic agents and their clinical uses |
| Q35222233 | Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema |
| Q36187050 | An emerging role for calcium sensitisation in the treatment of heart failure |
| Q43826641 | Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium |
| Q30632646 | Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. |
| Q36384536 | Ca2+-sensitisers--a promising option to treat heart failure? |
| Q38939243 | Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe? |
| Q37851240 | Cardiac inotropes: current agents and future directions |
| Q46915198 | Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs |
| Q46057255 | Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis. |
| Q37607413 | Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure |
| Q28242602 | Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin |
| Q41584608 | Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? |
| Q46143451 | Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction |
| Q35049090 | Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium |
| Q33763274 | Effect of levosimendan in experimental verapamil-induced myocardial depression |
| Q28366891 | Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model |
| Q48564458 | Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy |
| Q44304021 | Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats |
| Q40169864 | Effect of pimobendan in patients with chronic heart failure. |
| Q46203477 | Effects of levosimendan on left atrial functions in patients with ischemic heart failure. |
| Q46653424 | Effects of levosimendan on left ventricular functional remodelling and exercise intolerance: a tissue Doppler study |
| Q31157664 | Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression |
| Q35772807 | Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure |
| Q55286667 | Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats. |
| Q44074134 | Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. |
| Q36479750 | Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex |
| Q53901244 | Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. |
| Q43653904 | Improved survival with simendan after experimental myocardial infarction in rats |
| Q42198249 | Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart |
| Q74062709 | Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium |
| Q38949815 | Intermittent levosimendan infusions in advanced heart failure: a real world experience |
| Q41089779 | Intracoronary Levosimendan during Ischemia Prevents Myocardial Apoptosis |
| Q44297394 | Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. |
| Q98899370 | Is myosin activation a new treatment for heart failure? |
| Q34257871 | Levosimendan |
| Q37774030 | Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties |
| Q97884755 | Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use |
| Q26738701 | Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper |
| Q42602858 | Levosimendan decreases intracranial pressure after hypothermic circulatory arrest in a porcine model |
| Q58781484 | Levosimendan for Pediatric Anomalous Left Coronary Artery From the Pulmonary Artery Undergoing Repair: A Single-Center Experience |
| Q45108007 | Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure |
| Q42919974 | Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure |
| Q48747845 | Levosimendan improves diastolic and systolic function in failing human myocardium. |
| Q36070389 | Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study |
| Q43686339 | Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery |
| Q34139035 | Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction |
| Q35159849 | Levosimendan restores the positive force-frequency relation in heart failure |
| Q44780770 | Levosimendan. Clinical indications of a new vasoactive substance |
| Q31440110 | Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure |
| Q35546635 | Levosimendan: Implications for Clinicians |
| Q36203088 | Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure |
| Q36284075 | Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure |
| Q34232063 | Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties |
| Q46892188 | Levosimendan: a promising treatment for myocardial stunning? |
| Q35592393 | Levosimendan: a review of its use in the management of acute decompensated heart failure |
| Q46186787 | Levosimendan: from basic science to clinical practice |
| Q35974991 | Life-threatening calcium channel blocker overdose and its management. |
| Q83816869 | Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure |
| Q46728107 | Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene |
| Q55341036 | Loss of Metabolic Flexibility in the Failing Heart. |
| Q36438459 | Medical and ventilatory treatment of acute heart failure: new insights |
| Q34952145 | Molecular actions of drugs that sensitize cardiac myofilaments to Ca2+. |
| Q33159912 | Myocardial infarction in the 31st week of pregnancy--case report |
| Q52143567 | New drugs in the treatment of heart failure. |
| Q34026094 | Overview of the management of pediatric heart failure |
| Q36114364 | Pharmacological mechanisms contributing to the clinical efficacy of levosimendan |
| Q38099679 | Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. |
| Q46404003 | Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition |
| Q40151421 | Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog |
| Q43667587 | Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases |
| Q34998466 | Review article: inotrope and vasopressor use in the emergency department |
| Q46638446 | Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure |
| Q47396402 | Successful Identification of Cardiac Troponin Calcium Sensitizers Using a Combination of Virtual Screening and ROC Analysis of Known Troponin C Binders |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q36007118 | The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. |
| Q47748898 | The effect of levosimendan in rat mesenteric ischemia/reperfusion injury |
| Q21131829 | The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium |
| Q36249074 | The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure |
| Q35117055 | The therapeutic potential of novel cardiotonic agents |
| Q36761355 | The utility of levosimendan in the treatment of heart failure |
| Q46790124 | Update on inotropic therapy in the management of acute heart failure |
| Q59789293 | Use of levosimendan in acute heart failure |
| Q51767459 | Use of β-blockade and levosimendan for separation from extracorporeal life support in an infant with postoperative diastolic dysfunction. |
| Q46497134 | Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases |
| Q80106735 | [Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure] |
| Q79387615 | [Role of Levosimendan in intensive care treatment of myocardial insufficiency] |
Search more.